ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Inventiva Sa

Inventiva Sa (0RNK)

7,62
0,00
(0,00%)
Geschlossen 04 Februar 5:30PM

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Current Price
7,62
Gebot
0,00
Fragen
0,00
Volumen
130
0,00 Tagesbereich 0,00
7,62 52-Wochen-Bereich 7,62
Marktkapitalisierung
Handelsende
7,62
Handelsbeginn
-
Letzte Trade
81
@
2.305
(O)
Letzter Handelszeitpunkt
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
286
Ausgegebene Aktien
52.116.000
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-1,09
Gewinn pro Aktie (EPS)
-2,12
Erlöse
23,16M
Nettogewinn
-110,43M

Über Inventiva Sa

Sektor
Biological Pds,ex Diagnstics
Branche
Biological Pds,ex Diagnstics
Hauptsitz
Daix, Fra
Gegründet
-
Inventiva Sa is listed in the Biological Pds,ex Diagnstics sector of the Londoner Börse with ticker 0RNK. The last closing price for Inventiva was 7,62 €. Over the last year, Inventiva shares have traded in a share price range of 7,62 € to 7,62 €.

Inventiva currently has 52.116.000 shares in issue. The market capitalisation of Inventiva is 397,12 € million. Inventiva has a price to earnings ratio (PE ratio) of -1.09.

0RNK Neueste Nachrichten

Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology

Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of...

Inventiva annonce la publication dans la revue « Journal of Hepatology » des résultats de l’étude clinique de preuve de concept initiée par un investigateur évaluant lanifibranor chez des patients atteints de DT2 et MASLD

Inventiva annonce la publication dans la revue « Journal of Hepatology » des résultats de l’étude clinique de preuve de concept initiée par un investigateur évaluant lanifibranor chez des patients...

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux Daix (France), New York City (New York, United States), January 24, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA...

Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux

Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux Daix (France), New York City (New York, Etats-Unis), le 24 janvier 2025 – Inventiva (Euronext Paris...

Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025

Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025 Daix (France), New York City (New York...

Résultats de LEGEND évaluant la combinaison de lanifibranor avec empagliflozine dans la MASH ont été sélectionnés pour présentation orale au EASL SLD Summit 2025

Résultats de LEGEND évaluant la combinaison de lanifibranor avec empagliflozine dans la MASH ont été sélectionnés pour présentation orale au EASL SLD Summit 2025 Daix (France), New York City (New...

Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference

Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference Daix (France), New York City (New York, United States), December 17, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA...

Inventiva annonce sa participation à la « 43rd Annual J.P. Morgan Healthcare Conference »

Inventiva annonce sa participation à la « 43rd Annual J.P. Morgan Healthcare Conference » Daix (France), New York City (New York, Etats Unis), le 17 décembre 2024 – Inventiva (Euronext Paris and...

Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million Inventiva secures €21.4 million leading to completion of...

Inventiva obtient 21,4 millions d'euros complétant la première tranche du financement multi-tranches annoncé précédemment d'un montant maximum de 348 millions d'euros

Inventiva obtient 21,4 millions d'euros complétant la première tranche du financement multi-tranches annoncé précédemment d'un montant maximum de 348 millions d'euros Inventiva lève...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1007.627.627.62817.62DE
4007.627.627.625637.62DE
12007.627.627.622867.62DE
26007.627.627.627677.62DE
52007.627.627.625317.62DE
156007.627.627.6219157.62DE
260007.627.627.6229747.62DE

0RNK - Frequently Asked Questions (FAQ)

What is the current Inventiva share price?
The current share price of Inventiva is 7,62 €
How many Inventiva shares are in issue?
Inventiva has 52.116.000 shares in issue
What is the market cap of Inventiva?
The market capitalisation of Inventiva is EUR 397,12M
What is the 1 year trading range for Inventiva share price?
Inventiva has traded in the range of 7,62 € to 7,62 € during the past year
What is the PE ratio of Inventiva?
The price to earnings ratio of Inventiva is -1,09
What is the cash to sales ratio of Inventiva?
The cash to sales ratio of Inventiva is 5,2
What is the reporting currency for Inventiva?
Inventiva reports financial results in EUR
What is the latest annual turnover for Inventiva?
The latest annual turnover of Inventiva is EUR 23,16M
What is the latest annual profit for Inventiva?
The latest annual profit of Inventiva is EUR -110,43M
What is the registered address of Inventiva?
The registered address for Inventiva is 50 RUE DE DIJON, DAIX, 21121
What is the Inventiva website address?
The website address for Inventiva is www.inventivapharma.com
Which industry sector does Inventiva operate in?
Inventiva operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
CRVCraven House Capital Plc
US$ 0,425
(70,00%)
55,91k
DEMGDeltex Medical Group Plc
0,05p
(25,00%)
22,83M
PYXPyx Resources Limited
2,50p
(23,46%)
671,42k
EMEEmpyrean Energy Plc
0,15p
(20,00%)
565,83M
SALTMicrosalt Plc
82,50p
(17,86%)
89,08k
LLAILunglife Ai Inc
1,85p
(-81,95%)
5,56M
SDYSpeedy Hire Plc
19,90p
(-27,64%)
20,6M
CASSCassell Capital Plc
0,075p
(-22,68%)
19,6M
INSPInspirit Energy Holdings Plc
0,0028p
(-22,22%)
306,22M
PNNPennon Group Plc
462,20p
(-20,03%)
4,73M
MSMNMosman Oil And Gas Limited
0,0425p
(6,25%)
1,51B
NTVONativo Resources Plc
0,0018p
(0,00%)
786,47M
EMEEmpyrean Energy Plc
0,15p
(20,00%)
565,83M
SYMESupply@me Capital Plc
0,0031p
(5,08%)
413,64M
TRPTower Resources Plc
0,0295p
(0,00%)
322,17M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock